FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
The FDA granted Jemperli (dostarlimab-gxly) a breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, marking its second designation for this population. Jemperli showed a 100% clinical complete response rate in a phase 2 trial, supporting its potential to improve treatment for patients with this condition.
Highlighted Terms
endometrial cancerrectal cancerlocally advanced mismatch repair deficient (dMMR)microsatellite instability-high (MSI-H) rectal cancerdMMR recurrent or advanced endometrial cancercarboplatinpaclitaxelJemperlidostarlimab-gxlyFDAdMMR recurrent or advanced solid tumorsMemorial Sloan Kettering Cancer CenterGSK plc
Related News
FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
The FDA granted Jemperli (dostarlimab-gxly) a breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, marking its second designation for this population. Jemperli showed a 100% clinical complete response rate in a phase 2 trial, supporting its potential to improve treatment for patients with this condition.